Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVZ-2471 for Post-Herpetic Neuralgia (Phase 2, Korea)
KCT0010718Phase 2Completed
- Sponsor
- Vivozon
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing VVZ-2471 capsules with Placebo capsules (2 arms). Primary endpoint: Primary analgesic efficacy. Started Dec 2024; status: completed.
02
Drugs
VVZ-2471
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on KCT0010718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010718.